The Distinction Between Brand and Generic Medications
Many patients are confused when they hear a different name for their medication. This is a common occurrence in pharmacology and is explained by the difference between a brand name and a generic name. A brand name, like Eliquis, is a proprietary name given by the manufacturer to market the drug. The generic name, in this case, apixaban, refers to the active chemical compound responsible for the medication's therapeutic effect. The original manufacturers, Bristol Myers Squibb (BMS) and Pfizer, hold the patent for the brand-name drug. When patients ask, "What is the new name for Eliquis?" they are often hearing the generic name, apixaban, which will eventually become more common as lower-cost generic versions become available.
The Active Ingredient: Apixaban
The active ingredient in Eliquis is apixaban, a type of blood thinner known as a Factor Xa inhibitor. Its purpose is to prevent blood clots from forming, which is crucial for patients with conditions like atrial fibrillation or those recovering from hip or knee replacement surgery. By inhibiting Factor Xa, a key protein in the blood-clotting process, apixaban effectively decreases the generation of thrombin, thereby reducing the risk of stroke or other systemic embolism. While the brand-name drug is manufactured by the BMS-Pfizer Alliance, the generic versions will be produced by other pharmaceutical companies once patent exclusivity expires.
The Status of Generic Apixaban Availability
Despite the FDA approving generic versions of apixaban in late 2019, they have not yet entered the market. The primary reason for this delay is ongoing patent litigation initiated by BMS and Pfizer to protect their market exclusivity for Eliquis. This legal process allows the original manufacturers to defend their patents and delay competition from generic drugmakers. A September 2021 court ruling upheld the patents, delaying the earliest projected generic launch until April 1, 2028, pending any further appeals. Patients should be aware that while generics are approved, their widespread availability is still some time away. This is why the brand name Eliquis remains the most prevalent name for this medication in the U.S. market.
Alternatives to Eliquis and What to Consider
For patients seeking alternatives due to cost concerns or side effects, other anticoagulant options are available. These alternatives include both newer-generation and older medications, each with its own benefits and considerations. Any decision to switch medications should be made in close consultation with a healthcare provider.
Comparing Oral Anticoagulants
| Feature | Eliquis (apixaban) | Xarelto (rivaroxaban) | Pradaxa (dabigatran) | Warfarin (Coumadin) |
|---|---|---|---|---|
| Mechanism of Action | Factor Xa inhibitor | Factor Xa inhibitor | Direct thrombin inhibitor | Vitamin K antagonist |
| Dosing Frequency | Twice daily | Once daily (for most uses) | Twice daily | Once daily (variable dose) |
| Routine Monitoring | Not typically required | Not typically required | Not typically required | Frequent blood tests (INR) required |
| Generic Availability | Delayed (approx. 2028) | Generic versions available | Generic versions available | Yes, widely available |
| Cost (Brand-Name) | Higher due to patent protection | Higher due to patent protection | Moderate | Lower due to generic status |
Recent Developments in Patient Access
Recognizing the cost burden for many patients, the BMS-Pfizer Alliance has introduced a new direct-to-patient program. As of September 2025, eligible uninsured or underinsured patients can access Eliquis at a significant discount through the Eliquis 360 Support program. This initiative aims to increase access and affordability for those who need it most, even while the brand name remains under patent protection. This does not mean the name has changed, but rather that new pathways to access the existing brand-name medication are being created.
How to Manage Your Medication Safely
- Never Discontinue Without Medical Advice: Stopping an anticoagulant like Eliquis prematurely can significantly increase the risk of serious thrombotic events, including stroke. A healthcare provider must manage any interruption or change in therapy.
- Understand Interactions: Be aware of other medications, over-the-counter drugs, and supplements that can interact with Eliquis, potentially increasing bleeding risk. Always inform your doctor about all medications you are taking.
- Refill in Advance: Ensure you have enough medication and refill your prescription before you run out to avoid missing doses.
Conclusion: The Name Remains, but Options Evolve
To conclude, there is no new name for Eliquis. The brand name Eliquis refers to the active ingredient apixaban, and this naming convention has remained consistent since its approval. The question often arises due to discussions around the much-anticipated, lower-cost generic alternatives, which are currently unavailable due to patent litigation but are expected to enter the market around 2028. In the interim, new patient support programs are being implemented by the manufacturer to help with affordability. Regardless of cost or market status, the most critical takeaway is to follow the precise instructions of a qualified healthcare professional regarding dosage and any potential changes to your anticoagulant regimen. For more detailed information on apixaban's mechanism and clinical trials, refer to the National Institutes of Health (NIH) resources.
